Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: BIIB stock price vs LOW: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at LOW's multiple
Needs LOW P/E.
Implied fair value · at BIIB's multiple
Needs BIIB P/E.
Price unavailable
Metric by metric
Where each company leads, and how wide the gap is.
Growth lag
Reported gross margin
Operating income + D&A
Lower is better
Not comparable
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
14 period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Complete market value, debt and cash evidence is required for enterprise value.
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
BIOGEN INC. · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
LOWES COMPANIES INC · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
PFIZER INC
BIIB vs PFE
JOHNSON & JOHNSON
BIIB vs JNJ
AMGEN INC
BIIB vs AMGN
ELI LILLY & Co
BIIB vs LLY
Natera, Inc.
BIIB vs NTRA
ILLUMINA, INC.
BIIB vs ILMN
HOME DEPOT, INC.
BIIB vs HD
SHERWIN WILLIAMS CO
BIIB vs SHW
WILLIAMS SONOMA INC
BIIB vs WSM
Tractor Supply Company
BIIB vs TSCO
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
Edwyn research
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe BIIB can sustain its superior margins and ROIC while avoiding valuation compression, then hold or accumulate selectively; otherwise, reduce exposure because the current price of $202.95 sits above the DCF range and the implied valuation points to -24.0% downside.
BIIB trades at a higher valuation than LOW on every provided multiple, with a P/E of 23.1x versus 17.5x, P/S of 3.0x versus 1.4x, and EV/Revenue of 3.4x versus 1.5x. The implied price of $154.15 versus the current $202.95 suggests -24.0% downside, while the current price sits above the top of the DCF range and above the historical band midpoint.
Supporting Metrics
